StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
NASDAQ:TTNP opened at $6.71 on Wednesday. Titan Pharmaceuticals has a 12 month low of $5.00 and a 12 month high of $16.60. The business’s 50-day moving average is $7.34 and its two-hundred day moving average is $7.09. The firm has a market capitalization of $6.10 million, a PE ratio of -0.82 and a beta of 1.33.
About Titan Pharmaceuticals
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- 3 Tickers Leading a Meme Stock Revival
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Hilton Demonstrates Asset Light is Right for Investors
- Why Invest in High-Yield Dividend Stocks?
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.